Discover how TP53 mutations in adult leukaemia impact treatment outcomes and potential strategies for improved patient care.

(FocalFinder/iStock/Getty Images Plus) Researchers have identified a previously unknown neurodevelopmental disorder ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts-including one oral presentation-for the ...

Unlock the latest liquid biopsy market data. Explore growth drivers, precision oncology shifts, and the tech fueling ...

Researchers assessed the feasibility of using large language models to match cancer patients with certain genetic mutations to appropriate clinical trials.

The idea that modern humans inherited DNA from Neanderthal ancestors is one of the 21st century’s most celebrated discoveries ...

Tempus AI TEM shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the ...

In this interview, Dr. Michelle Fraser highlights how base editing and AI-designed enzymes are expanding therapeutic ...

AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...

Explore the recent advances in fuzzing, including the challenges and opportunities it presents for high-integrity software ...

It couldn’t come at a better time, considering that cancer rates are rising among younger women.